Testing a tool to guide treatment for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with triple-negative breast cancer that has spread or is locally advanced.
- You are about to start or change to a new systemic therapy (chemo or other treatments that travel through your body).
- You are willing to have an extra biopsy (needle sample) of your breast tumor or a related spot before starting treatment.
- You are willing to have about 3 tablespoons of blood drawn for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether it is safe and practical to take multiple small tissue samples (biopsies) from different sites of your breast cancer over time. The goal is to learn how breast cancer changes as it grows, which could help doctors develop better treatments.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This trial is testing whether checking DNA from your blood (circulating tumor DNA) can help doctors choose the best neoadjuvant (pre-surgery) treatment for HER2-positive or triple-negative breast cancer. It aims to personalize therapy based on how your tumor responds.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.